News Releases News Releases 7/28/20 News Releases 7/28/20 Identification of p-tau217 in Blood Samples Offers Early Detection of Alzheimer’s Disease and Builds Interest in C₂N Intellectual Property Read More News Releases 5/14/20 News Releases 5/14/20 C₂N Diagnostics Receives $20M Program-Related Investment from GHR Foundation to Bring Alzheimer’s Blood Test to the Clinic Read More News Releases 12/9/19 News Releases 12/9/19 C₂N Diagnostics Reports High Accuracy of APTUS™-Aβ Blood Test for Detecting Early Alzheimer’s Disease Pathology Read More News Releases 12/2/19 News Releases 12/2/19 C₂N Diagnostics to Report Results of APTUS™-Aβ Blood Test for Alzheimer’s Disease Brain Pathology Read More News Releases 1/29/19 News Releases 1/29/19 C₂N Diagnostics Receives Breakthrough Device Designation from U.S. FDA for Blood Test to Screen for Alzheimer’s Disease Risk Read More News Releases 1/25/17 News Releases 1/25/17 AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy Read More News Releases 12/9/16 News Releases 12/9/16 C₂N Diagnostics Reports Phase 1 Study Results of C2N-8E12 (ABBV-8E12) – Anti-Tau Antibody – in Subjects with Progressive Supranuclear Palsy Read More News Releases 10/13/16 News Releases 10/13/16 C₂N Diagnostics Completes Phase 1 Clinical Study of C2N-8E12 (ABBV-8E12) Among Individuals with Progressive Supranuclear Palsy Read More News Releases 10/13/15 News Releases 10/13/15 CurePSP Forms Subsidiary to Promote Clinical Trials Read More News Releases 8/7/15 News Releases 8/7/15 C₂N and AbbVie Announce FDA Orphan Drug Designation of C2N-8E12 (ABBV-8E12) for the Treatment of Progressive Supranuclear Palsy Read More News Releases 3/19/15 News Releases 3/19/15 AbbVie and C₂N Enter Into a Worldwide License Agreement for Alzheimer's Disease Therapy Read More News Releases 7/14/14 News Releases 7/14/14 C₂N Expands Partnership with Washington U to Commercialize Blood Test for Detection of Early AD Read More News Releases 9/19/13 News Releases 9/19/13 C₂N Diagnostics Makes Three New Hires to Speed Commercialization of Diagnostics and Theranostics Read More News Releases 7/12/13 News Releases 7/12/13 C₂N Diagnostics Announces Collaborative Research Agreement with Cambridge Isotopes Read More News Releases 6/14/13 News Releases 6/14/13 SILK-Abeta Study Detects Early Changes in Brain Amyloid Pathology Read More News Releases 1/2/13 News Releases 1/2/13 Pre-Competitive Consortium to Develop, Standardize, and Validate Preclinical Aged Canine Model of AD Read More News Releases 8/30/12 News Releases 8/30/12 Newly Study in PNAS Links LDL Receptor to Abeta Brain Clearance Read More News Releases 8/7/12 News Releases 8/7/12 C₂N Diagnostics Receives SBIR Award to Study Novel Tau Biomarkers in Alzheimer's Disease Read More News Releases 3/18/10 News Releases 3/18/10 C₂N Diagnostics Announces Key New Hire and $1M+ Grant from Anonymous Donor to Support Alzheimer’s Biomarkers and Diagnostics Programs Read More News Releases 12/17/09 News Releases 12/17/09 C₂N Diagnostics Awarded "Fast Track" SBIR by NIA/NIH Read More Newer Posts Older Posts
News Releases 7/28/20 News Releases 7/28/20 Identification of p-tau217 in Blood Samples Offers Early Detection of Alzheimer’s Disease and Builds Interest in C₂N Intellectual Property Read More
News Releases 5/14/20 News Releases 5/14/20 C₂N Diagnostics Receives $20M Program-Related Investment from GHR Foundation to Bring Alzheimer’s Blood Test to the Clinic Read More
News Releases 12/9/19 News Releases 12/9/19 C₂N Diagnostics Reports High Accuracy of APTUS™-Aβ Blood Test for Detecting Early Alzheimer’s Disease Pathology Read More
News Releases 12/2/19 News Releases 12/2/19 C₂N Diagnostics to Report Results of APTUS™-Aβ Blood Test for Alzheimer’s Disease Brain Pathology Read More
News Releases 1/29/19 News Releases 1/29/19 C₂N Diagnostics Receives Breakthrough Device Designation from U.S. FDA for Blood Test to Screen for Alzheimer’s Disease Risk Read More
News Releases 1/25/17 News Releases 1/25/17 AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy Read More
News Releases 12/9/16 News Releases 12/9/16 C₂N Diagnostics Reports Phase 1 Study Results of C2N-8E12 (ABBV-8E12) – Anti-Tau Antibody – in Subjects with Progressive Supranuclear Palsy Read More
News Releases 10/13/16 News Releases 10/13/16 C₂N Diagnostics Completes Phase 1 Clinical Study of C2N-8E12 (ABBV-8E12) Among Individuals with Progressive Supranuclear Palsy Read More
News Releases 10/13/15 News Releases 10/13/15 CurePSP Forms Subsidiary to Promote Clinical Trials Read More
News Releases 8/7/15 News Releases 8/7/15 C₂N and AbbVie Announce FDA Orphan Drug Designation of C2N-8E12 (ABBV-8E12) for the Treatment of Progressive Supranuclear Palsy Read More
News Releases 3/19/15 News Releases 3/19/15 AbbVie and C₂N Enter Into a Worldwide License Agreement for Alzheimer's Disease Therapy Read More
News Releases 7/14/14 News Releases 7/14/14 C₂N Expands Partnership with Washington U to Commercialize Blood Test for Detection of Early AD Read More
News Releases 9/19/13 News Releases 9/19/13 C₂N Diagnostics Makes Three New Hires to Speed Commercialization of Diagnostics and Theranostics Read More
News Releases 7/12/13 News Releases 7/12/13 C₂N Diagnostics Announces Collaborative Research Agreement with Cambridge Isotopes Read More
News Releases 6/14/13 News Releases 6/14/13 SILK-Abeta Study Detects Early Changes in Brain Amyloid Pathology Read More
News Releases 1/2/13 News Releases 1/2/13 Pre-Competitive Consortium to Develop, Standardize, and Validate Preclinical Aged Canine Model of AD Read More
News Releases 8/30/12 News Releases 8/30/12 Newly Study in PNAS Links LDL Receptor to Abeta Brain Clearance Read More
News Releases 8/7/12 News Releases 8/7/12 C₂N Diagnostics Receives SBIR Award to Study Novel Tau Biomarkers in Alzheimer's Disease Read More
News Releases 3/18/10 News Releases 3/18/10 C₂N Diagnostics Announces Key New Hire and $1M+ Grant from Anonymous Donor to Support Alzheimer’s Biomarkers and Diagnostics Programs Read More
News Releases 12/17/09 News Releases 12/17/09 C₂N Diagnostics Awarded "Fast Track" SBIR by NIA/NIH Read More
